134 related articles for article (PubMed ID: 32090101)
1. Detection of
Chu M; Zhu Y; Hu J; Zhang Z; Luo M; Ma X
Biomed Res Int; 2020; 2020():6124106. PubMed ID: 32090101
[TBL] [Abstract][Full Text] [Related]
2. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
Chen YL; Chen WL; Cheng YC; Lin MC; Yang SC; Tsai HW; Lin CC; Su WC; Chow NH; Ho CL
PLoS One; 2021; 16(9):e0257152. PubMed ID: 34559836
[TBL] [Abstract][Full Text] [Related]
4. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
5. Using Disposable Membrane Cell Collector to Enrich Lung Adenocarcinoma Cells in Bloody Pleural Effusion for Anaplastic Lymphoma Kinase Fusion Gene Detection.
Guo X; Zhao J; Du Y; Liu Y; Ma Y; Wang R; Ji X; Wu J; Dong L
Acta Cytol; 2021; 65(3):235-241. PubMed ID: 33631757
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
[TBL] [Abstract][Full Text] [Related]
7. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
[TBL] [Abstract][Full Text] [Related]
8. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
[TBL] [Abstract][Full Text] [Related]
9. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
Yu Y; Qian J; Shen L; Ji W; Lu S
Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
[TBL] [Abstract][Full Text] [Related]
10. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
11. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
[TBL] [Abstract][Full Text] [Related]
12. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.
Kim TH; Woo S; Yoon SH; Halpenny DF; Han S; Suh CH
AJR Am J Roentgenol; 2019 Nov; 213(5):1059-1072. PubMed ID: 31414902
[No Abstract] [Full Text] [Related]
13. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
[TBL] [Abstract][Full Text] [Related]
14. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
[TBL] [Abstract][Full Text] [Related]
15. Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients.
Shin S; Kim J; Kim Y; Cho SM; Lee KA
Clin Chem Lab Med; 2017 Oct; 55(12):1962-1969. PubMed ID: 28306520
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors.
Carter J; Miller JA; Feller-Kopman D; Ettinger D; Sidransky D; Maleki Z
Ann Am Thorac Soc; 2017 Jul; 14(7):1169-1176. PubMed ID: 28557526
[TBL] [Abstract][Full Text] [Related]
17. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
18. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
19. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
20. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.
Liu L; Zhan P; Zhou X; Song Y; Zhou X; Yu L; Wang J
PLoS One; 2015; 10(3):e0117032. PubMed ID: 25785456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
